Alcohol use disorder, or AUD, is a rising health crisis that often goes undiagnosed. And many patients that are diagnosed with AUD do not receive appropriate pharmacologic intervention or even a referral. Join Drs. Levesque and Cowan in this case-based educational program as they provide critical diagnostic and treatment strategies for use in the office/clinic setting and the Emergency Department.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Annie Levesque, MD, MSc
Medical Director, Opioid Treatment Program, Mount Sinai West
Icahn School of Medicine at Mount Sinai
New York, NY
No relevant relationships reported
Ethan A. Cowan, MD
Professor of Emergency Medicine
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Cowan has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Indivior, LLC
Contracted Research: Gilead LLC
- Cindy Davidson has nothing to disclose.
- Barry A. Fiedel, PhD, has nothing to disclose.
- Amanda Hilferty has nothing to disclose.
- John Maeglin has nothing to disclose.
- Tim Person has nothing to disclose.
- Colleen Resnick has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Employ validated screening tools to identify patients who should receive further assessment of alcohol use disorder (AUD).
- Utilize brief interventional strategies to overcome patient reticence to accepting treatment for AUD.
- Utilize motivational interviewing to overcome patient reticence to accepting treatment for AUD.
- Formulate strategies to ensure the appropriate use of pharmacotherapy for moderate to severe AUD in the office/clinic setting.
- Formulate strategies to ensure the appropriate use of pharmacotherapy for moderate to severe AUD in the ED setting, inclusive of discharge instructions that include referral.
This activity is designed to meet the educational needs of emergency medicine physicians, primary care physicians, PAs, APNs, nurses, addiction specialists, and psychiatrists.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.1 AAPA Category 1 CME credits. Approval is valid until January 17, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Alkermes, Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Sanam Loghavi, MD
Razelle Kurzrock, MD, FACP
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches0.25 credits
Benjamin Levy, MD
Alexander Spira, MD, PhD, FACP
Pediatric Narcolepsy: Addressing the Challenges in Its Recognition, Diagnosis, and Management0.25 credits
Michael J. Thorpy, MD
Anne Marie Morse, DO